SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:prod.swepub.kib.ki.se:146348719"
 

Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:146348719" > Antithrombotic ther...

  • Gorog, DA (författare)

Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a joint position paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI)

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2020-02-12
  • Oxford University Press (OUP),2021

Nummerbeteckningar

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:146348719
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:146348719URI
  • https://doi.org/10.1093/ehjcvp/pvaa009DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Timely and effective antithrombotic therapy is critical to improving outcome, including survival, in patients with acute coronary syndrome (ACS). Achieving effective platelet inhibition and anticoagulation, with minimal risk, is particularly important in high-risk ACS patients, especially those with cardiogenic shock (CS) or those successfully resuscitated following out-of-hospital cardiac arrest (OHCA), who have a 30-50% risk of death or a recurrent ischaemic event over the subsequent 30 days. There are unique challenges to achieving effective and safe antithrombotic treatment in this cohort of patients that are not encountered in most other ACS patients. This position paper focuses on patients presenting with CS or immediately post-OHCA, of presumed ischaemic aetiology, and examines issues related to thrombosis and bleeding risk. Both the physical and pharmacological impacts of CS, namely impaired drug absorption, metabolism, altered distribution and/or excretion, associated multiorgan failure, co-morbidities and co-administered treatments such as opiates, targeted temperature management, renal replacement therapy and circulatory or left ventricular assist devices, can have major impact on the effectiveness and safety of antithrombotic drugs. Careful attention to the choice of antithrombotic agent(s), route of administration, drug-drug interactions, therapeutic drug monitoring and factors that affect drug efficacy and safety, may reduce the risk of sub- or supra-therapeutic dosing and associated adverse events. This paper provides expert opinion, based on best available evidence, and consensus statements on optimising antithrombotic therapy in these very high-risk patients, in whom minimising the risk of thrombosis and bleeding is critical to improving outcome.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Price, S (författare)
  • Sibbing, D (författare)
  • Baumbach, A (författare)
  • Capodanno, D (författare)
  • Gigante, BKarolinska Institutet (författare)
  • Halvorsen, S (författare)
  • Huber, K (författare)
  • Lettino, M (författare)
  • Leonardi, S (författare)
  • Morais, J (författare)
  • Rubboli, A (författare)
  • Siller-Matula, JM (författare)
  • Storey, RF (författare)
  • Vranckx, P (författare)
  • Rocca, B (författare)
  • Karolinska Institutet (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:European heart journal. Cardiovascular pharmacotherapy: Oxford University Press (OUP)7:2, s. 125-1402055-68452055-6837

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy